Altered Serum IgG Levels to α-Synuclein in Dementia with Lewy Bodies and Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Koehler, Niklas K U ^a   Stransky, Elke ^a   Shing, Mona ^a   Gaertner, Susanne ^a   Meyer, Mirjam ^a   Schreitmüller, Brigitte ^a   Leyhe, Thomas ^a   Laske, Christoph ^a   Maetzler, Walter ^b   Kahle, Phillipp ^b   Celej, Maria S ^c   Jovin, Thomas M ^c   Fallgatter, Andreas J ^a   Batra, Anil ^a   Buchkremer, Gerhard ^a   Schott, Klaus ^a   Richartz Salzburger, Elke ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY;

AGED; AGING; ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MINI MENTAL STATE EXAMINATION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN TARGETING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AUTOANTIBODIES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEWY BODY DISEASE; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84878534880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064649     Document Type: Article

References (59)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
2. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, et al. (2006) What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 129: 729-735.
3. Kotzbauer PT, Trojanowsk JQ, Lee VM, (2001) Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17: 225-232.
4. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J, (1989) Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol 46: 651-657.
5. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325.
6. Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A, (2012) CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. J Neural Transm 119: 861-875.
7. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349: 162-166.
8. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133: 713-726.
9. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM, (2009) Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16: 363-369.
10. Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, et al. (2002) Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 58: 1435-1436.
11. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, et al. (2007) Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 101: 749-756.
12. Gruden MA, Sewell RD, Yanamandra K, Davidova TV, Kucheryanu VG, et al. (2011) Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol 233: 221-227.
13. Gruden MA, Yanamandra K, Kucheryanu VG, Bocharova OR, Sherstnev VV, et al. (2012) Correlation between Protective Immunity to alpha-Synuclein Aggregates, Oxidative Stress and Inflammation. Neuroimmunomodulation 19: 334-342.
14. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, et al. (2011) alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 6: e18513.
15. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, et al. (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80: 169-175.
16. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA, (2012) alpha-Synuclein and Anti-alpha-Synuclein Antibodies in Parkinson's Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls. PLoS One 7: e52285.
17. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55-59.
18. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K, (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176: 98-104.
19. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, et al. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285: 9262-9272.
20. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW, (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506.
21. Li JY, Englund E, Holton JL, Soulet D, Hagell P, et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14: 501-503.
22. Jucker M, Walker LC, (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532-540.
23. Miller G, (2008) Parkinson's disease. Signs of disease in fetal transplants. Science 320: 167.
24. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, et al. (2012) Antibody-Aided Clearance of Extracellular alpha-Synuclein Prevents Cell-to-Cell Aggregate Transmission. J Neurosci 32: 13454-13469.
25. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857-868.
26. McGeer PL, McGeer EG, (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
27. Roodveldt C, Christodoulou J, Dobson CM, (2008) Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 12: 1820-1829.
28. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
29. Galpern WR, Lang AE, (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59: 449-458.
30. Jellinger KA, (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5: 118-121.
31. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H, (2010) Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120: 1-12.
32. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, et al. (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
33. Morgan D, (2005) Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2: 261-266.
34. Schulz-Schaeffer WJ, (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 120: 131-143.
35. Fiala M, Cribbs DH, Rosenthal M, Bernard G, (2007) Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis 11: 457-463.
36. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A, (2007) Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82: 235-246.
37. Antonaci S, Garofalo AR, Chicco C, Polignano AV, Pugliese P, et al. (1990) Senile dementia, Alzheimer type: a distinct entity in the immunosenescence? J Clin Lab Anal 4: 16-21.
38. Richartz E, Batra A, Simon P, Wormstall H, Bartels M, et al. (2005) Diminished production of proinflammatory cytokines in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 19: 184-188.
39. Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, et al. (2005) Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? J Psychiatr Res 39: 535-543.
40. Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, et al. (2007) Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res 41: 174-178.
41. Du Y, Dodel R, Hampel H, Buerger K, Lin S, et al. (2001) Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801-805.
42. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, et al. (2005) Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 57: 813-816.
43. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, et al. (2001) Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 49: 808-810.
44. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, et al. (2005) Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280: 17458-17463.
45. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, et al. (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 3: 29-39.
46. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, et al. (2002) Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37: 943-948.
47. Xu S, Gaskin F, (1997) Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech Ageing Dev 94: 213-222.
48. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, et al. (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 1219: 169-179.
49. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855.
50. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T, (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159: 439-447.
51. Szabo P, Relkin N, Weksler ME, (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7: 415-420.
52. Brendza RP, Holtzman DM, (2006) Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 20: 118-123.
53. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
54. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, et al. (2008) Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 283: 4714-4722.
55. Nasstrom T, Goncalves S, Sahlin C, Nordstrom E, Screpanti Sundquist V, et al. (2011) Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS One 6: e27230.
56. Dighiero G, Rose NR, (1999) Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 20: 423-428.
57. Silverstein AM, (2001) Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat Immunol 2: 279-281.
58. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, et al. (1998) Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216: 117-137.
59. Lacroix-Desmazes S, Mouthon L, Kaveri SV, Kazatchkine MD, Weksler ME, (1999) Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol 19: 26-34.